医药生物技术专栏 |
|
|
|
|
聚乙二醇重组人干扰素及其药品通用名称命名 |
任跃明 |
国家药典委员会 北京 100061 |
|
PEGylated Recombinant Human Interferon and Nomenclature |
REN Yue-ming |
Chinese Pharmacopeia Commission, Beijing 100061, China |
[1] Kang J S, Deluca P P, Lee K C. Emerging PEGylated drugs. Expert Opin Emerg Drugs,2009,14(2):363-380.
[2] Bailon P I, Won C Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv, 2009,6(1):1-16.
[3] Francesco M Veronese, Anna Mero. The impact of PEGylation on biological therapies. Biodrugs, 2008, 22 (5): 315-329.
[4] Robert W Payne, Brian M Murphy, Mark Cornell. Product development issues for PEGylated proteins. Pharmaceutical Development and Technology, 2011, 16(5): 423-440.
[5] Fee C J, Van Alstine J A. PEG-proteins: Reaction engineering and separation issues. Chem Engineer Sci, 2006,61:924-939.
[6] Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv, 2006,13:399-409.
[7] Fee C J. Size comparison between proteins PEGylated with branched and linear Poly(ethylene glycol) molecules. Biotechnol Biotechnol Bioengineer, 2007,98:725-731.
[8] WHO. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances Executive Summary.09/2013. http://www.who.int/medicines/services/inn/56th_Executive_Summary.pdf?ua=1.
[9] 任跃明. 国际非专利药品名(INN)在我国生物制品命名领域的应用.中国药品标准, 2008,9(3):189-194. Ren Y M. Prospect of International Nonproprietary Name in Chinese Biologicals.Drug Standard of China,2008,9(3):189-194.
[10] 《中国药典》. 2010年版. 三部.附录5. Pharmacopoeia of the People's Republic of China. 2010 Edition. Vol Ⅲ. Appendix 5.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|